Drugs / ALA-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07518329 | Apr 2026 → Mar 2030 expected | leukemia, non-Hodgkin lymphoma | Arovella Therapeutics Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALA-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07518329 ↗ |
| Modality | Cell therapy | “ALA-101, an allogeneic, off-the-shelf CD19-directed CAR-iNKT cell therapy” NCT07518329 ↗ |
| Route | Intravenous | “Single IV infusion of ALA-101” NCT07518329 ↗ |
| Target | CD19 | “ALA-101, an allogeneic, off-the-shelf CD19-directed CAR-iNKT cell therapy” NCT07518329 ↗ |